Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
It is currently available in tablet and injectable dosage forms
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
Subscribe To Our Newsletter & Stay Updated
